An Open Label, Single Dose, Randomized, Two-Way Cross-Over Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination Rifampicin + Isoniazid (Myrin 2, Pfizer Inc) Tablet With The Reference Drug (Rimactane, Novartis Sandoz) Capsule In Healthy Filipino Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2015
At a glance
- Drugs Isoniazid/rifampicin (Primary) ; Rifampicin
- Indications Tuberculosis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 02 Jun 2011 Planned end date changed from 1 May 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.